Category: CovidienSyndicate content

JNJ looks to bolster "subscale" cardiovascular business | The week in medtech M&A

July 23, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere; Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Siemens sells clinical microbiology biz to Beckman Coulter

Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere

July 16, 2014 by Brad Perriello

YYmeta

Covidien promotes Hanson to group president role | Personnel Moves

July 22, 2014 by Brad Perriello

Covidien names Bryan Hanson group president, with oversight of all of the medical device company's businesses.

Covidien promotes Hanson to group president role | Personnel Moves

Medtronic-Covidien merger may get caught in anti-inversion legislation | Medtech legal news for the week of July 21, 2014

July 21, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Medtronic fights tax dodging rhetoric in Covidien merger; Travelers holds out on BD's $67M coverage claim; Abbott CEO defends inversions amid corporate exodus furor; Steris, Medtrica win legal fees in Cygnus Medical patent spat;

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

July 16, 2014 by Arezu Sarvestani

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

Abbott CEO defends inversions amid corporate exodus furor

July 18, 2014 by Arezu Sarvestani

Abbott chairman & CEO Miles White chides critics of corporate inversions as Capitol Hill mulls legislation to strip tax benefits for companies that shift their headquarters overseas.

Abbott CEO defends inversions amid corporate exodus furor

Medtronic fights tax dodging rhetoric in Covidien merger

July 17, 2014 by Arezu Sarvestani

Medtronic ensures shareholders that the company remains beholden to (nearly) all U.S. corporate taxes as it shifts its headquarters overseas.

Medtronic fights tax evasion rhetoric in Covidien merger

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

July 16, 2014 by Arezu Sarvestani

Lawmakers aim to prohibit companies from shifting their headquarters overseas in order to evade U.S. taxes, a measure that would apply retroactively to deals such as Medtronic's $43 billion acquisition of Covidien.

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien to launch Emprint soft tissue ablation device

July 16, 2014 by Brad Perriello

Covidien says it plans to launch the Emprint soft tissue ablation device for treating inoperable liver cancer during the 3rd quarter.

Covidien to launch Emprint soft tissue ablation device

Covidien (NYSE:COV) said today that it's launching its Emprint soft tissue ablation system, aiming at the market for inoperable liver cancers.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp